Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous nicorandil for cardioprotection in CABG (real-world study)
ChiCTR2300069877Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nicorandil in coronary arteriosclerosis (2 arms), sponsored by Tongji Hospital. Primary endpoint: Major adverse cardiovascular events (MACE) at 30 days post-surgery. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300069877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069877.